Menopause not aldosterone-to-renin ratio predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients

American Journal of Hypertension

Volumn 21, Issue 9, 2008, Pages 976-982

  Olivieri, Oliviero ^a   Pizzolo, Francesca ^a   Ciacciarelli, Alberto ^b   Corrocher, Roberto ^a   Signorelli, Denise ^c   Falcone, Salvatore ^c   Blengio, Gian S ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b Bussolengo Health District   (Italy)

^c Cattedra di Medicina Interna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; DOXAZOSIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KANRENOATE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; RENIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; PLASMA RENIN ACTIVITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; ALDOSTERONE; BLOOD PRESSURE; CANRENOATE POTASSIUM; FEMALE; HUMANS; HYPERTENSION; MALE; MENOPAUSE; MIDDLE AGED; RECEPTORS, MINERALOCORTICOID; RENIN; VERAPAMIL;

EID: 50249117619     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.234     Document Type: Article

References (34)

1. Gordon RD, Ziezak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Phisiol 1993; 20:296-298.
2. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary aldosteronism in essential hypertensives: prevalence, biochemical profile and molecular biology. J Clin Endocrinol Metab 2000; 85:1863-1867.
3. Stowasser M, Gordon RD. Prevalence and diagnostic workup of primary aldosteronism: new knowledge and new approaches. Nephrology 2001; 6:119-126.
4. Young WF. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 2003; 114:2208-2213.
5. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-2300.
6. Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999; 48:756-760.
7. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertension 2001; 19:353-361.
8. Mahmud A, Mahgoub M, Hall M, Feely J. Does aldosterone to renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertension 2005; 18:1631-1635.
9. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertenion 2004; 22:2217-2226.
10. Hood S, Cannon J, Foo R, Brown M. Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing. Clin Med 2005; 5:55-60.
11. Sartori M, Calo LA, Mascagna V, Realdi A, Macchini L, Ciccariello L, De Toni R, Cattelan F, Pessina AC, Semplicini A. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 2006; 19:373-379.
12. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar BB, Weissman P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892-896.
13. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999; 353:40.
14. Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C,Corgnati A, Falcone S, Corrocher R, Micchi A, Cressoni C, Blengio G. Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004;89:4221-4226.
15. Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 2007; 30:111-117.
16. Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? (Pro). Hypertension 2007; 50:447-453.
17. Kaplan NM. Is there an unrecognized epidemic of primary aldosteronism? (Con). Hypertension 2007; 50:454-458.
18. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism, J Hypertension 2001; 19:353-361.
19. Park S, Kim JB, Shim CY, Ko YG, Choi D, Jang Y, Chung N. The influence of serum aldosterone and the aldosterone-renin ratio on pulse wave velocity in hypertensive patients. J Hypertens 2007;25:1279-1283.
20. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005;18:50-55.
21. Duffy SJ, Biegelsen ES, Eberhardt RT, Kahn DF, Kingwell BA, Vita JA. Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension 2005; 46:707-713.
22. Sartori M, Calà LA, Mascagna V, Realdi A, Macchini L, Ciccariello L, De Toni R, Cattelan F, Pessina AC, Semplicini A. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 2006;19:373-379.
23. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, O'Donnell CJ, Musone SL, Camargo AL, Drake JA, Levy D, Hirschhorn JN, Vasan RS. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007;49:846-856.
24. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004; 43:918-923.
25. Pechere-Bertschi A, Burnier M. Gonadal steroids, salt-sensitivity and renal function. Curr Opin Nephrol Hypertens 2007; 16:16-21.
26. Gambling L, Dunford S, Wilson CA, McArdle HJ, Baines DL. Estrogen and progesterone regulate α, β, and γENaC subunit mRNA levels in female rat kidney. Kidney Int 2004;65:1774-1781.
27. Michlig S, Harris M, Loffing J, Rossier BC, Firsov D. Progesterone down-regulates the open probability of the amiloride-sensitive epithelial sodium channel via a Nedd4-2-dependent mechanism. J Biol Chem 2005; 280:38264-38370.
28. White WB, Pitt B, Prston RA, Hanes V. Antihypertensive effects of drospirenone with 17β-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005; 112:1979-1984.
29. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-β-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48:246-253.
30. Sica DA. Drospirenone: an antihypertensive in waiting. Hypertension 2006; 48:205-206.
31. Oelkers W. Dropsirenone, a progestogen with antimineralcorticoid properties: a short review. Mol Cell Endocrinol 2004; 217:255-261.
32. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
33. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
34. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:1-7.